Moleculin Biotech, Inc. (MBRX) AI Dilution Summary

Estimated cash was $10,245,978 as of 2026-09-23. That figure is rolled forward from $7,262,000 at 2026-06-30, against estimated monthly burn of $2,128,000. The funding channel is the ATM program with Roth Capital Partners, LLC, authorised to $19,700,000, with 68,759 shares sold since the program began through 2026-09-23; sales after 2026-09-23 are not yet reported.